PERSPECTIVE

1. Evolution-driven crosstalk between glioblastoma and the tumor microenvironment

REVIEW

1. Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
2. Expert opinion on translational research for advanced glioblastoma treatment
3. Development of glioblastoma organoids and their applications in personalized therapy
4. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

ORIGINAL ARTICLE

1. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance